Piperacillin
- Generic Name
- Piperacillin
- Brand Names
- Pipracil, Zosyn
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N5O7S
- CAS Number
- 66258-76-2
- Unique Ingredient Identifier
- 9I628532GX
- Background
Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.
- Indication
For the treatment of polymicrobial infections.
- Associated Conditions
- Animal bite, Bacterial Infections, Bone and Joint Infections, Community Acquired Pneumonia (CAP), Gynecological Infection, Infection, Mixed, Intraabdominal Infections, Lower Respiratory Tract Infection (LRTI), Nosocomial Pneumonia, Pelvic Infections, Septicemia, Skin and skin structure infections, Urinary Tract Infection, Uncomplicated Urethritis gonococcal caused by Neisseria Gonorrhoeae
Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery
Not Applicable
Completed
- Conditions
- Thyroid DiseaseParathyroid Disease
- Interventions
- First Posted Date
- 2013-03-06
- Last Posted Date
- 2013-03-06
- Lead Sponsor
- Ito Hospital
- Target Recruit Count
- 2164
- Registration Number
- NCT01805856
- Locations
- 🇯🇵
Ito Hospital, Tokyo, Japan
Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
Phase 4
Completed
- Conditions
- Respiratory Tract InfectionsUrinary Tract Infections
- Interventions
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
- Target Recruit Count
- 2000
- Registration Number
- NCT01760109
- Locations
- 🇨🇳
Chongqing Red Cross hospital, Chongqing, China
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Not Applicable
- Conditions
- NeutropeniaHematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT01714557
- Locations
- 🇨🇳
Chinese PLA general hospital, Beijing, Beijing, China
Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Rhode Island Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT01697059
- Locations
- 🇺🇸
Hasbro Children's Hospital (Rhode Island Hospital), Providence, Rhode Island, United States
A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
Phase 4
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Intermittent, short infusion Ticarcillin-clavulanateDrug: Continuous infusion Ticarcillin-clavulanateDrug: Intermittent, short infusion Cefepime
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- The Alfred
- Target Recruit Count
- 50
- Registration Number
- NCT01667094
- Locations
- 🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
Phase 4
Completed
- Conditions
- Infectious Disease
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 14
- Registration Number
- NCT01198925
- Locations
- 🇧🇪
University Hospital Ghent, Ghent, Belgium
Study Evaluating BLI-489 and Piperacillin in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00894439
Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)
Phase 3
Completed
- Conditions
- Complicated Intra-Abdominal Infections
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT00389987
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
Phase 3
Completed
- Conditions
- Bone Marrow SuppressionFever, Sweats, and Hot FlashesInfectionLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 859
- Registration Number
- NCT00003805
- Locations
- 🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇨🇭Universitaetsspital, Zurich, Switzerland
🇨🇭Ospedale San Giovanni, Bellinzona, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath